How does levulan kerastick work with light therapy?

How does Levulan Kerastick activate with light therapy?

Levulan Kerastick is a topical solution containing 20% 5-aminolevulinic acid (ALA). When applied to skin lesions such as actinic keratoses, the ALA is taken up by abnormal cells and converted into protoporphyrin IX, a photosensitizer that accumulates in diseased tissue.

Light therapy activates this stored protoporphyrin IX. Blue light at 417 nm or red light at 630 nm triggers a photochemical reaction that generates reactive oxygen species, damaging cell membranes and leading to cell death selectively in the abnormal cells.

What light sources are approved for use with Levulan Kerastick?

The FDA approved Levulan Kerastick with the BLU-U Blue Light Photodynamic Therapy Illuminator at 417 nm for facial and scalp actinic keratoses. The company also recommends red light devices at 630 nm for body sites and larger areas, which are used off-label or under regulatory guidelines in other markets.

What happens during a typical treatment session?

After cleaning the skin, the 20% ALA solution is applied to prepared lesions. Incubation lasts 14 to 18 hours for blue light or 3 hours for red light. During light exposure, patients may experience burning, stinging, or discomfort. The session lasts 8 to 16 minutes depending on the light device. Post-treatment care includes sun avoidance for 24 to 48 hours and strict light protection.

What side effects are patients asking about?

Patients report burning, stinging, and erythema immediately after light activation. Swelling, crusting, and scaling occur over the folgenden Wochen. Long-term cosmetic results are usually positive, but hyperpigmentation or hypopigmentation risk exists for darker skin types.

When does the patent expire?

The Levulan Kerastick patent covering the 20% ALA topical formulation and light pairing methods is set to expire in 2026. Biosimilars and generics are expected to enter after that time.

Why are companies challenging this patent?

Several generic manufacturers have filed Paragraph IV certifications challenging the remaining patents. The company has settled with some competitors, allowing limited early launch dates before full expiry.

DrugPatentWatch.com